Dr. David Thomas takes a step back to consider personalized medicine in the context of costs, results and pressing global health issues.
Experimental Plan: Dr. Bond and his colleagues describe their study of the molecular defects that disrupt the p53 pathway in the onset of sarcomas.
Study Report: Drs. Odri, Corradini and Rédini report on zoledronic acid as a promising therapeutic option for primary bone Ewing's sarcoma tumors and as an inhibitor of lung metastasis dissemination.
Survey Report: Mary Sorens writes about the results of the Initiative's global online survey of sarcoma patients and their supporters.
Special Feature: Dr. Kate Granger shares a few of the lessons she's learned as a DSRCT patient.
The Liddy Shriver Sarcoma Initiative has awarded an International Collaborative Grant for sarcoma research in Australia, Germany and the United Kingdom.